Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegylated liposomal dexamethasone sodium phosphate - Enceladus Pharmaceuticals

Next Previous
Drug Profile

Pegylated liposomal dexamethasone sodium phosphate - Enceladus Pharmaceuticals

Alternative Names: Dexamethasone sodium phosphate - Enceladus Pharmaceuticals; Enc 0313; Liposomal dexamethasone - Enceladus Pharmaceuticals; Oncocort; PEG-liposomal dexamethasone sodium phosphate

Latest Information Update: 22 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enceladus Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple myeloma; Prostate cancer

Most Recent Events

  • 22 Feb 2022 No development reported - Phase-I/II for Multiple myeloma (Monotherapy, Second-line therapy or greater) in Germany (IV)
  • 22 Feb 2022 No development reported - Phase-I/II for Prostate cancer (Hormone refractory, Metastatic disease, Monotherapy) in Netherlands (IV)
  • 01 Aug 2020 Enceladus Pharmaceuticals terminates phase I/II trial in Multiple myeloma (Second-line therapy or greater, Monotherapy) in Germany due to patient enrolment issues (IV) (EudraCT2014-005137-32)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top